EN DE
Watch Sichuan Biokin Pharmaceutical Co. Ltd. A for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Sichuan Biokin Pharmaceutical Co. Ltd. A stock ¥146, price ¥259, that is 43.5% below the price, quality 32 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE100006FN4

SB Sichuan Biokin Pharmaceutical Co. Ltd. A logo Thin data Nov 10, 2026

Sichuan Biokin Pharmaceutical Co. Ltd. A

688506 · SHG
Very expensive, weak quality

Our calculation puts a fair price 44% below what the stock costs today.

Low debt
Expensive Growth (revenue 3y +53.0 %/yr in CNY)
Revenue last quarter 11% below a year ago.
Fair value ¥146.26 · Strongly overvalued
Quality 32/100
Loss-making · -62.0% net margin (TTM)
Negative free cash flow
Trails peers (0/10)
Narrow moat 10/100 · thin data
Thin data
Estimate⚠ Small free float
Watch Sichuan Biokin Pharmaceutical Co. Ltd. A for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥410.00 ¥32.05 Fair Value ¥146.26 Jan 2023 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

46‑month range ¥32.05 – ¥410.00 · fair‑value band ¥109.69 – ¥182.82 · the ¥258.88 price screens above the ¥146.26 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Sichuan Biokin Pharmaceutical Co. Ltd. A in your weekly email

Every Wednesday you see whether Sichuan Biokin Pharmaceutical Co. Ltd. A is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sichuan Biokin Pharmaceutical Co.,Ltd. engages in the research and development, production, and supply of biomedicine in the fields of antibody drug conjugate, guidance navigation and control, and antibody radionuclide conjugate in China and internationally.

Show moreShow less

It offers anesthesia, parenteral nutrition, anti-infectives, pediatrics, and traditional Chinese medicines. The company was founded in 1996 and is headquartered in Chengdu, China.

Stock analysis

Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) currently trades at ¥258.88, while our estimate is ¥146.26, 44% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: ¥109.69 (bear) to ¥182.82 (bull), the price of ¥258.88 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Sichuan Biokin Pharmaceutical Co. Ltd. A reported revenue of 2.5B CNY in FY2025 versus 797M CNY in FY2021, a compound +33.4%/yr. Reported net income was −1.1B CNY in FY2025.

Key figures

Market cap 107B CNY (≈ $16.0B) Large · P/S ratio 38.8 · EPS (TTM) ¥−3.66 · Dividend yield 0.1% · Net margin −62.0% · Return on equity −42.5% · Return on assets (EBIT) −5.7% (5-year average) · Operating margin −926%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 33% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −44%, 688506 screens richer than that median.

Fair Value

Bear ¥109.69 Fair Value ¥146.26 Bull ¥182.82
Price ¥258.88 · Downside -43.5%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 32/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 9
How much profit the company makes from its sales and capital
Quality Growth 1
Are margins and returns getting better?
Cashflow 6
Do the profits arrive as real cash?
Financial strength 92
Debt, balance sheet and risk of trouble
Investment 18
Does it invest with discipline instead of growing at any price?
Low Volatility 56
How calm the share price moves, does not count
Price momentum 22
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 17
Distance to the 52-week high, does not count
New shares 62
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−56.7%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+53.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−11.7% (2021) → −29.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

688506 screens overvalued: fair value 44% below the price. Compare with Merck KGaA →

Compare Sichuan Biokin Pharmaceutical Co. Ltd. A with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 606 stocks

Beats the industry median on 0/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −43.5% · Below median
Profitability
Return on assets −9.2% · Bottom 25%
Net margin (12 months) −62.0% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −10.6% · Bottom 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.40× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 16.14× · Priciest 25%
P/S (12 months) 42.14× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 18
FUTURE (revenue growth)0 · sector 25
PAST (return on equity)0 · sector 25
HEALTH (low debt)80 · sector 96
DIVIDEND (yield)2 · sector 31

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.46 $113.53 +38% vs 688506
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥48.55 ¥55.21 +14% vs 688506
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,905 ₹1,983 +4% vs 688506
Haleon plc HLN $9.06 $8.62 −5% vs 688506
Merck KGaA MRK €149.35 €109.18 −27% vs 688506
Galderma Group GALD CHF 188.55 CHF 109.80 −42% vs 688506
Takeda Pharmaceutical Company TAK $20.93 $11.34 −46% vs 688506
Teva Pharmaceutical Industries Limited TEVA $42.40 $20.74 −51% vs 688506
Sandoz Group SDZ CHF 83.38 CHF 39.70 −52% vs 688506
Divi's Laboratories Limited DIVISLAB ₹11,566 ₹1,567 −86% vs 688506

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sichuan Biokin Pharmaceutical Co. Ltd. A: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sichuan Biokin Pharmaceutical Co. Ltd. A Fair Value". https://www.fairvalue-calculator.com/stock/688506

Frequently asked questions

Is Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is ¥146.26 versus a price of ¥258.88, about 44% lower (overvalued).
What is the fair value of 688506?
Our estimate for Sichuan Biokin Pharmaceutical Co. Ltd. A is ¥146.26 (as of Nov 10, 2026), built from audited fundamentals. The current price: ¥258.88.
What is the quality score of 688506?
Sichuan Biokin Pharmaceutical Co. Ltd. A has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Our calculated price target is the estimate of ¥146.26 (as of Nov 10, 2026). Cautious scenario ¥109.69, optimistic scenario ¥182.82. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Sichuan Biokin Pharmaceutical Co. Ltd. A stock forecast for 2026?
Our estimate puts fair value at ¥146.26, about 44% lower versus a price of ¥258.88 (overvalued). Cautious scenario ¥109.69, optimistic scenario ¥182.82. The calculation is refreshed regularly with new filings.
What is the revenue of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Sichuan Biokin Pharmaceutical Co. Ltd. A reported trailing-twelve-month revenue of about 2.5B CNY (latest available figure, as of Nov 10, 2026).
Does Sichuan Biokin Pharmaceutical Co. Ltd. A pay a dividend?
Sichuan Biokin Pharmaceutical Co. Ltd. A currently shows a dividend yield of 0.08% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Sichuan Biokin Pharmaceutical Co. Ltd. A has a dividend yield of 0.1%.
What is the intrinsic value of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sichuan Biokin Pharmaceutical Co. Ltd. A it is ¥146.26 per share (as of Nov 10, 2026), against a price of ¥258.88.
Is Sichuan Biokin Pharmaceutical Co. Ltd. A stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 688506 trades above its calculated fair value: price ¥258.88, fair value ¥146.26, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688506?
No. The price is what the market pays today (¥258.88); the fair value is what the company's own numbers justify (¥146.26). For Sichuan Biokin Pharmaceutical Co. Ltd. A the two are ¥112.62 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sichuan Biokin Pharmaceutical Co. Ltd. A worth?
The market values Sichuan Biokin Pharmaceutical Co. Ltd. A at about 107B CNY (market capitalisation, as of Nov 10, 2026). Per share that is ¥258.88; our models calculate a fair value of ¥146.26 per share.
What do the bullish and bearish scenarios say about 688506?
Our models span a range for Sichuan Biokin Pharmaceutical Co. Ltd. A: cautious scenario ¥109.69, base ¥146.26, optimistic ¥182.82 per share (as of Nov 10, 2026, price ¥258.88). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Balance-sheet figures for Sichuan Biokin Pharmaceutical Co. Ltd. A (as of Nov 10, 2026): return on equity −42.5%, debt of 0.40 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is 688506 from its 52-week high?
Sichuan Biokin Pharmaceutical Co. Ltd. A trades at ¥258.88, about 33% below its 52-week high of ¥388.28 and 27% above the low of ¥204.58 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of ¥146.26 is for.
Which stocks are comparable to Sichuan Biokin Pharmaceutical Co. Ltd. A?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sichuan Biokin Pharmaceutical Co. Ltd. A stock attractive at the current price?
The data as of Nov 10, 2026: price ¥258.88, calculated fair value ¥146.26 (−44%), Quality Score 32/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Sichuan Biokin Pharmaceutical Co. Ltd. A itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The closing price on Nov 10, 2026 was ¥258.88. Our estimate is ¥146.26, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sichuan Biokin Pharmaceutical Co. Ltd. A right now?
The price sits above even our optimistic bull case (¥182.82). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Sichuan Biokin Pharmaceutical Co. Ltd. A

How large is the market capitalisation of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The market capitalisation of Sichuan Biokin Pharmaceutical Co. Ltd. A is 107B CNY (≈ $16.0B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The price-to-sales ratio of Sichuan Biokin Pharmaceutical Co. Ltd. A is 38.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Earnings per share at Sichuan Biokin Pharmaceutical Co. Ltd. A are ¥−3.66. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The dividend yield of Sichuan Biokin Pharmaceutical Co. Ltd. A is 0.1%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The net margin of Sichuan Biokin Pharmaceutical Co. Ltd. A is −62.0% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The return on equity (ROE) of Sichuan Biokin Pharmaceutical Co. Ltd. A is −42.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
On an EBIT basis the return on assets of Sichuan Biokin Pharmaceutical Co. Ltd. A is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
The operating margin of Sichuan Biokin Pharmaceutical Co. Ltd. A is −926% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sichuan Biokin Pharmaceutical Co. Ltd. A (688506)?
Revenue at Sichuan Biokin Pharmaceutical Co. Ltd. A is growing −10.6% versus a year earlier (3y avg +53.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) generate?
The free cash flow of Sichuan Biokin Pharmaceutical Co. Ltd. A is −1.1B CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sichuan Biokin Pharmaceutical Co. Ltd. A (688506) carry?
The net debt of Sichuan Biokin Pharmaceutical Co. Ltd. A is 55.1M CNY (fiscal year 2023). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sichuan Biokin Pharmaceutical Co. Ltd. A in the live analysis

One click puts Sichuan Biokin Pharmaceutical Co. Ltd. A on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.